

Special Issue

Thoracic Malignancies: From Pathophysiology to Novel Therapeutic Approaches

Message from the Guest Editor

Mesothelioma is a rare, but aggressive cancer type, originating from mesothelium tissues covering the lungs (pleura), heart (pericardium), abdomen (peritoneum) and testes (tunicae testis). However, 90% of mesothelioma cases are of malignant pleural mesothelioma (MPM), which is usually associated with exposure to asbestos. MPM involves tumour suppressor gene mutation instead of oncogenes, so targeted therapies are rarely applied. In the last two decades, chemotherapy has been the only first-line treatment for unresectable MPM. Immunotherapy was approved by FDA in 2020, but only a small population of patients benefit from it. Further studies are needed to understand this disease and develop novel therapeutic approaches. In this collection, we aim to include research focused on the histological, molecular, and biological mechanisms of MPM and pleural effusion, the potential biomarkers for different treatment strategies, advanced diagnostic techniques, novel therapies for MPM (targeted, metabolomic, and immune therapies), and promising models of MPM (organoids, tissue slices, and mouse models).

Guest Editor

Dr. Yanyun Gao

University Hospital Bern, Bern, Switzerland

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/203073

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).